Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Asan Medical Center
Centre Oscar Lambret
Centre Oscar Lambret
Ankara University
Incheon St.Mary's Hospital
Shanghai Cancer Hospital, China
Delfi Diagnostics Inc.
University of Kentucky
UNICANCER
Cook Group Incorporated
Regeneron Pharmaceuticals
Karolinska University Hospital
University of Iowa
Erasmus Medical Center
Abramson Cancer Center at Penn Medicine
AstraZeneca
Wake Forest University Health Sciences
University of Pennsylvania
Grupo Espanol de Tumores Neuroendocrinos
Columbia University
Hoffmann-La Roche
Immuneering Corporation
Memorial Sloan Kettering Cancer Center
Imugene Limited
Eurofarma Laboratorios S.A.
Creative Biosciences (Guangzhou) Co., Ltd.
Sun Yat-sen University
Boston Scientific Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
IRCCS San Raffaele
National Institutes of Health Clinical Center (CC)
Karolinska Institutet
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Taproot Health
Alanya Alaaddin Keykubat University
Astellas Pharma Inc
AstraZeneca
Astellas Pharma Inc
European Organisation for Research and Treatment of Cancer - EORTC
Memorial Sloan Kettering Cancer Center
University Hospital, Basel, Switzerland
CancerCare Manitoba
Merck Sharp & Dohme LLC
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advaxis, Inc.